ストックスクリーナーアプリを入手
6.89
1.08%
-0.07
前日終値:
$6.96
開ける：
$6.98
24時間の取引高:
832.99K
Relative Volume:
0.30
時価総額：
$1.03B
収益：
-
当期純損益:
$-134.24M
株価収益率:
-3.8927
EPS:
-1.77
ネットキャッシュフロー:
$-121.34M
1週間 パフォーマンス:
+13.43%
1か月 パフォーマンス:
+34.74%
6か月 パフォーマンス:
+177.62%
1年 パフォーマンス:
+62.38%
1日の値動き範囲:
$6.87
$7.18
1週間の範囲:
$5.85
$7.18
52週間の値動き範囲:
$1.285
$7.18
Annexon Inc Stock (ANNX) Company Profile
ANNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
6.885 | 1.04B | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.84 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.20 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
825.34 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.46 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.86 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-23 | 開始されました | Chardan Capital Markets | Buy |
| 2024-03-01 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-30 | 開始されました | Wells Fargo | Overweight |
| 2023-05-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-05-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | BTIG Research | Buy |
| 2021-11-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-09-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | BofA Securities | Buy |
| 2020-08-18 | 開始されました | Cowen | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
すべてを表示
Annexon Inc (ANNX) 最新ニュース
Annexon (NASDAQ:ANNX) Hits New 12-Month HighHere's Why - MarketBeat
Annexon Inc (NASDAQ:ANNX) Advances Complement Biology Platform - Kalkine Media
Annexon (NASDAQ:ANNX) Stock Price Up 9.5%Still a Buy? - MarketBeat
Aug Chart Watch: What are the risks of holding Annexon IncMarket Sentiment Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX? - Yahoo Finance
Annexon (ANNX) Is Up 15.6% After EMA Filing For GBS Antibody Tanruprubart Has The Bull Case Changed? - simplywall.st
Levels Update: Will Annexon Inc benefit from government policyWeekly Investment Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome - Yahoo Finance
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon (NASDAQ:ANNX) Trading Down 5.9%Here's Why - MarketBeat
Key facts: Annexon to Submit FDA Application for Dry AMD Treatment; Key Milestones Expected in 2026 - TradingView — Track All Markets
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead - MarketBeat
Annexon, Inc. Updates on Strategic Developments and Product Pipeline - TradingView — Track All Markets
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Annexon Biosciences stock rating reiterated by Cantor Fitzgerald - Investing.com Nigeria
Annexon (NASDAQ:ANNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Pharma News: Will Annexon Inc. stock benefit from AI adoptionWeekly Market Report & Weekly Chart Analysis and Guides - Bộ Nội Vụ
Hedge Fund and Insider Trading News: Ray Dalio, Chris Rokos, Steven Cohen, Bill Ackman, Israel Englander, Scott Bessent, Citadel Investment Group, Eisler Capital, Virco Mfg Corp (VIRC), Annexon Inc (ANNX), and More - Insider Monkey
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - The Manila Times
Press Telegram - FinancialContent
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-01-10 21:17:27 - Улправда
Is Annexon Inc. stock safe for conservative investorsJuly 2025 Catalysts & Long-Term Safe Return Strategies - ulpravda.ru
Is Annexon Inc. stock oversold or undervaluedMarket Growth Review & Risk Controlled Swing Trade Alerts - Улправда
Will Annexon Inc. stock beat EPS estimates2025 Pullback Review & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Annexon Inc. stock continue upward momentumJuly 2025 Weekly Recap & Daily Momentum Trading Reports - Улправда
Institutional Investors Have a Lot Riding on Annexon, Inc. (NASDAQ:ANNX) With 68% Ownership - 富途牛牛
Annexon (ANNX) Seeks EMA Approval for Guillain-Barre Syndrome Dr - GuruFocus
Annexon Submits Tanruprubart Marketing Authorization Application To The European Medicines Agency For Guillain-Barré Syndrome - TradingView — Track All Markets
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - manilatimes.net
Annexon Submits Tanruprubart Marketing Authorization - GlobeNewswire
Annexon, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Quiver Quantitative
Annexon (NASDAQ:ANNX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Annexon stock rises after director purchases shares - MSN
Insider Buying: William Carson Acquires Additional Shares of Ann - GuruFocus
Insider Buying: Annexon (NASDAQ:ANNX) Director Purchases 4,115 Shares of Stock - MarketBeat
Annexon (NASDAQ:ANNX) Stock Price Down 6.9%Should You Sell? - MarketBeat
What analysts say about Annexon Inc stockMorning Star Patterns & Small Capital Investment Tips - earlytimes.in
Breakout Zone: Will Annexon Inc stock maintain growth story2025 Price Momentum & Growth Oriented Trading Recommendations - moha.gov.vn
Chardan Capital initiates coverage of Annexon (ANNX) with buy recommendation - MSN
Aug Macro: Will WAVE stock continue upward momentumExit Point & Risk Controlled Swing Trade Alerts - moha.gov.vn
Bollinger Bands Expand on Nahar Capital and Financial Services Limited Volatility AheadMerger & Acquisition Updates & Advanced Stock Screening Tools - earlytimes.in
Annexon (NASDAQ:ANNX) Upgraded at Chardan Capital - MarketBeat
Clear Street asserts buy rating on Annexon, Inc. (ANNX) amid progress on pipeline development - MSN
Chardan Capital Initiates Coverage on ANNX with a Buy Rating | A - GuruFocus
Chardan Initiates Annexon at Buy With $16 Price Target - marketscreener.com
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating By Investing.com - Investing.com South Africa
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating - Investing.com
Annexon (ANNX) price target increased by 27.19% to 14.79 - MSN
Annexon, Inc.(NasdaqGS: ANNX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Annexon Inc (ANNX) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.08%
大文字化:
|
ボリューム (24 時間):